Challenge Strain FA1090
Cross-source consensus on Challenge Strain FA1090 from 1 sources and 4 claims.
1 sources · 4 claims
Dosage & preparation
Preparation
Where it comes from
Other
Highlighted claims
- The study uses N. gonorrhoeae strain FA1090 variant A26 for challenge. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
- FA1090 variant A26 is resistant to streptomycin but susceptible to ciprofloxacin, cefixime, and cephalosporins used for treatment. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
- Before inoculation, bacteria are selected for a predominantly piliated, Opacity protein-negative phenotype expressing the lacto-N-neotetraose LOS epitope. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
- The target delivered dose is about 1.0 x 10^6 colony forming units and is expected to infect about 80% of inoculated participants. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol